Transcriptional and immunohistochemical profiling of patient samples has revealed that high GBP1 signatures were associated with tumor reduction in breast cancer and SKCM (Ascierto et al., 2012; Wang et al., 2018). Here, GBP1 is linked to breast carcinoma.